Hepatotoxicity of Rifampin-Pyrazinamide and Isoniazid Preventive Therapy and Tuberculosis Treatment
Open Access
- 15 August 2004
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 39 (4), 488-496
- https://doi.org/10.1086/422645
Abstract
Background. Severe liver injury has been attributed to preventive treatment of latent tuberculosis infection with a 2-month course of rifampin-pyraziKeywords
This publication has 20 references indexed in Scilit:
- Treatment, Tuberculosis, and Human Leukocyte AntigenAmerican Journal of Respiratory and Critical Care Medicine, 2002
- Evaluation of Clinical and Immunogenetic Risk Factors for the Development of Hepatotoxicity during Antituberculosis TreatmentAmerican Journal of Respiratory and Critical Care Medicine, 2002
- Control and prevention of tuberculosis in the United Kingdom: Code of Practice 2000Thorax, 2000
- Frequency and type of reactions to antituberculosis drugs: Observations in routine treatmentTubercle and Lung Disease, 1996
- Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in miceAntimicrobial Agents and Chemotherapy, 1992
- A Double-blind Placebo-controlled Clinical Trial of Three Antituberculosis Chemoprophylaxis Regimens in Patients with Silicosis in Hong KongAmerican Review of Respiratory Disease, 1992
- Less Is More: Short-course Preventive Therapy of TuberculosisAmerican Review of Respiratory Disease, 1989
- Tracheobronchopathia Osteochondroplastica Presenting as Right Middle Lobe CollapseChest, 1988
- The hepatic toxicity of antituberculosis regimens containing isoniazid, rifampicin and pyrazinamideTubercle, 1977